nach oben

vorheriger Artikel Sicherheitsaspekte des gynäkologischen Ultrasch...

Tipp

UpDate 2018: Kupferspirale, Kupferkette, Kupferperlen-Ball

Zeitschrift:: Journal für Gynäkologische Endokrinologie/Schweiz > Ausgabe 4/2018

Autor:: Dr. Allessandra Tramontana

Wichtige Hinweise

Dieser Beitrag wird auch im Journal für Gynäkologische Endokrinologie/Österreich 2018, https://doi.org/10.1007/s41974-018-0073-5 veröffentlicht.

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Richter R (1909) Ein Mittel zur Verhütung der Konzeption. Dtsch Med Wochenschr 35:1525 CrossRef

Pust K (1923) Ein brauchbarer Frauenschutz. Dtsch Med Wochenschr 49:952

Wildemeersch D, van der Pas H, Thiery M et al (1988) The Copper-Fix (Cu-Fix): a new concept in IUD technology. Adv Contracept 4(3):197–205 PubMedCrossRef

Baram I, Weinstein A, Trussell J (2014) The IUB, a newly invented IUD: a brief report. Contraception 89(2):139–141 PubMedCrossRef

Anteby E, Revel A, Ben-Chetrit A et al (1993) Intrauterine device failure: relation to its location within the uterine cavity. Obstet Gynecol 81(1):112–114 PubMed

O’Brien PA, Kulier R, Helmerhorst FM et al (2008) Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception 77(5):318–327 PubMedCrossRef

De la Cruz D, Cruz A, Arteaga M, Castillo L, Tovalin H (2005) Blood copper levels in Mexican users of the T380A IUD. Contraception 72(2):122–125 PubMedCrossRef

Hostynek JJ, Maibach HI (2004) Copper hypersensitivity: dermatologic aspects. Dermatol Ther 17(4):328–333 PubMedCrossRef

WHO Scientific Group on the Mechanism of Action Safety and Efficacy of Intrauterine Devices & World Health Organization (1987) Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. World Health Organization technical report series, Bd. 753, S 1–91

10.

Sagiroglu N (1971) Phagocytosis of spermatozoa in the uterine cavity of woman using intrauterine device. Int J Fertil 16(1):1–14 PubMed

11.

Ammala M, Nyman T, Strengell L, Rutanen EM (1995) Effect of intrauterine contraceptive devices on cytokine messenger ribonucleic acid expression in the human endometrium. Fertil Steril 63(4):773–778 PubMedCrossRef

12.

Tetrault AM, Richman SM, Fei X, Taylor HS (2009) Decreased endometrial HOXA10 expression associated with use of the copper intrauterine device. Fertil Steril 92(6):1820–1824 PubMedCrossRef

13.

Alvarez F, Brache V, Fernandez E et al (1988) New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 49(5):768–773 PubMedCrossRef

14.

Ortiz ME, Croxatto HB, Bardin CW (1996) Mechanisms of action of intrauterine devices. Obstet Gynecol Surv 51(12 Suppl):S42–S51 PubMedCrossRef

15.

Seleem S, Hills FA, Salem HT et al (1996) Mechanism of action of the intrauterine contraceptive device: evidence for a specific biochemical deficiency in the endometrium. Hum Reprod 11(6):1220–1222 PubMedCrossRef

16.

Patai K, Szilagyi G, Noszal B, Szentmariay I (2003) Local tissue effects of copper-containing intrauterine devices. Fertil Steril 80(5):1281–1283 PubMedCrossRef

17.

Rivera R, Yacobson I, Grimes D (1999) The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 181(5 Pt 1):1263–1269 PubMedCrossRef

18.

Rabe T, Bruckner C (2010) Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin in Zusammenarbeit mit dem Berufsverband der Frauenärzte

19.

Guleria K, Agarwal N, Mishra K et al (2004) Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: Can Cu-T prevent endometrial cancer? J Obstet Gynaecol Res 30(3):181–187 PubMedCrossRef

20.

Grimes DA, Mishell DR Jr. (2008) Intrauterine contraception as an alternative to interval tubal sterilization. Contraception 77(1):6–9 PubMedCrossRef

21.

Peterson HB, Xia Z, Hughes JM et al (1996) The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative review of sterilization. Am J Obstet Gynecol 174(4):1161–1168 (discussion 8–70) PubMedCrossRef

22.

Sivin I, Stern J (1994) Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 61(1):70–77 PubMedCrossRef

23.

United Nations Development Programme’ Correspondence, United Nations Population Fund, World Health Organization, World Bank, Special Programme of Research, Development and Research Training in Human Reproduction (1997) Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception 56(6):341–352

24.

Farley TM, Rosenberg MJ, Rowe PJ et al (1992) Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339(8796):785–788 PubMedCrossRef

25.

Lee NC, Rubin GL, Borucki R (1988) The intrauterine device and pelvic inflammatory disease revisited: new results from the Women’s Health Study. Obstet Gynecol 72(1):1–6 PubMed

26.

Persson E, Holmberg K, Dahlgren S, Nilsson L (1983) Actinomyces israelii in the genital tract of women with and without intra-uterine contraceptive devices. Acta Obstet Gynecol Scand 62(6):563–568 PubMedCrossRef

27.

Lippes J (1999) Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 180(2 Pt 1):265–269 PubMedCrossRef

28.

Westhoff C (2007) IUDs and colonization or infection with actinomyces. Contraception 75(6 Suppl):S48–S50 PubMedCrossRef

29.

Hubacher D, Reyes V, Lillo S et al (2006) Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. Hum Reprod 21(6):1467–1472 PubMedCrossRef

30.

Rivera R, Chen-Mok M, McMullen S (1999) Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. Contraception 60(3):155–160 PubMedCrossRef

31.

Lowe RF, Prata N (2013) Hemoglobin and serum ferritin levels in women using copper-releasing or levonorgestrel-releasing intrauterine devices: a systematic review. Contraception 87(4):486–496 PubMedCrossRef

32.

Hubacher D, Chen PL, Park S (2009) Side effects from the copper IUD: do they decrease over time? Contraception 79(5):356–362 PubMedPubMedCentralCrossRef

33.

Arrowsmith ME, Aicken CR, Saxena S, Majeed A (2012) Strategies for improving the acceptability and acceptance of the copper intrauterine device. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd008896.pub2 PubMedCrossRef

34.

Wu JP, Pickle S (2014) Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception 89(6):495–503 PubMedCrossRef

35.

Hubacher D (2007) Copper intrauterine device use by nulliparous women: review of side effects. Contraception 75(6 Suppl):S8–S11 PubMedCrossRef

36.

Lyus R, Lohr P, Prager S (2010) Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81(5):367–371 PubMedCrossRef

37.

ACOG practice bulletin (2005) Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol 105(1):223–232 CrossRef

38.

Sivin I, Schmidt F (1987) Effectiveness of IUDs: a review. Contraception 36(1):55–84 PubMedCrossRef

39.

World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on the Safety and Efficacy of Fertility Regulating Methods (1990) The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3,5 and 7 years of use—results from three randomized multicentre trials. Contraception 42(2):141–158 CrossRef

40.

Sivin I (1991) Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 78(2):291–298 PubMed

41.

The World Health Organization’s Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Intrauterine Devices for Fertility Regulation (1985) A multinational case-control study of ectopic pregnancy. Clin Reprod Fertil 3(2):131–143

42.

Marchbanks PA, Annegers JF, Coulam CB et al (1988) Risk factors for ectopic pregnancy. A population-based study. JAMA 259(12):1823–1827 PubMedCrossRef

43.

Ory HW (1981) Ectopic pregnancy and intrauterine contraceptive devices: new perspectives. The Women’s Health Study. Obstet Gynecol 57(2):137–144 PubMed

44.

Edelman DA, Porter CW (1987) The intrauterine device and ectopic pregnancy. Contraception 36(1):85–96 PubMedCrossRef

45.

Skjeldestad FE (1997) How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 76(7):684–690 PubMedCrossRef

46.

Rasheed SM, Abdelmonem AM (2011) Complications among adolescents using copper intrauterine contraceptive devices. Int J Gynaecol Obstet 115(3):269–272 PubMedCrossRef

47.

Shimoni N (2010) Intrauterine contraceptives: a review of uses, side effects, and candidates. Semin Reprod Med 28(2):118–125 PubMedCrossRef

48.

Vasquez P, Schreiber CA (2010) The missing IUD. Contraception 82(2):126–128 PubMedCrossRef

49.

Chen CP, Hsu TC, Wang W (1998) Ileal penetration by a multiload-Cu 375 intrauterine contraceptive device. A case report with review of the literature. Contraception 58(5):295–304 PubMedCrossRef

50.

Adoni A, Chetrit BA (1991) The management of intrauterine devices following uterine perforation. Contraception 43(1):77–81 PubMedCrossRef

51.

Zakin D, Stern WZ, Rosenblatt R (1981) Complete and partial uterine perforation and embedding following insertion of intrauterine devices. II. Diagnostic methods, prevention, and management. Obstet Gynecol Surv 36(8):401–417 PubMedCrossRef

52.

Cortessis VK, Barrett M, Brown Wade N et al (2017) Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol 130(6):1226–1236 PubMedCrossRef

53.

O’Brien PA, Marfleet C (2001) Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd003282 PubMedCrossRef

54.

van Kets H, Vrijens M, Van Trappen Y, Delbarge W, van der Pas H, Temmerman M et al (1995) The frameless GyneFix intrauterine implant: a major improvement in efficacy, expulsion and tolerance. Adv Contracept 11(2):131–142 PubMedCrossRef

55.

Wildemeersch D, Van Kets H, Vrijens M, Delbarge W, Van Trappen Y, Temmerman M et al (1997) Intrauterine contraception in adolescent women. The GyneFix intrauterine implant. Ann N Y Acad Sci 816:440–450 PubMedCrossRef

56.

Meirik O, Rowe PJ, Peregoudov A, Piaggio G, Petzold M (2009) The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8‑year multicenter randomized comparative trial. Contraception 80(2):133–141 PubMedCrossRef

57.

O’Brien PA, Marfleet C (2005) Frameless versus classical intrauterine device for contraception. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd003282.pub2 PubMedCrossRef

58.

Van Kets H, Van der Pas H, Thiery M et al (1997) The GyneFix implant systems for interval, postabortal and postpartum contraception: a significant advance in long-term reversible contraception. International Study Group on Intrauterine Drug Delivery. Eur J Contracept Reprod Health Care 2(1):1–13 PubMedCrossRef

59.

Wildemeersch D (2007) New frameless and framed intrauterine devices and systems—an overview. Contraception 75(6 Suppl):S82–S92 PubMedCrossRef

60.

Unal C, Eser A, Tozkir E, Wildemeersch D (2018) Comparison of expulsions following intracesarean placement of an innovative frameless copper-releasing IUD (Gyn-CS(R)) versus the TCu380A: a randomized trial. Contraception. https://doi.org/10.1016/j.contraception.2018.03.034 PubMedCrossRef

61.

Eser A, Unal C, Albayrak B, Wildemeersch D (2018) Clinical experience with a novel anchored, frameless copper-releasing contraceptive device for intra-caesarean insertion. Eur J Contracept Reprod Health Care 23(4):255–259 PubMedCrossRef

62.

Baram I, Weinstein A, Seidman DS (2014) A three-dimensional way to prevent pregnancy: the IUB intra uterine ball - a newly introduced IUD in clinical trials. J Obstet Gynaecol India 64(2):152–154 PubMedPubMedCentralCrossRef

63.

Wiebe E, Trussell J (2016) Discontinuation rates and acceptability during 1 year of using the intrauterine ball (the SCu380A). Contraception 93(4):364–366 PubMedCrossRef

64.

Ocon Medical (2016) Interim first year performance of the IUB SCu300A in comparison with the IUS TCu380A intrauterine device

65.

Ocon Medical (2017) Sicherheit und Wirksamkeit des IUB™ SCu300B (MIDI) nach vorliegenden Pharmakovigilanz-Berichten

Titel: UpDate 2018: Kupferspirale, Kupferkette, Kupferperlen-Ball
Autor:: Dr. Allessandra Tramontana
Publikationsdatum: 01.12.2018
Schlagwort: Kontrazeption
DOI: https://doi.org/10.1007/s41975-018-0072-y
Verlag: Springer Vienna
Zeitschrift: Journal für Gynäkologische Endokrinologie/Schweiz Revue de Endocrinologie Gynécologique
Ausgabe 4/2018
Print ISSN: 1995-6924
Elektronische ISSN: 2520-8500

Bildnachweise

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Editorial

Mitteilungen der Schweizerischen Menopausgesellschaft/SMG

Alternative Therapien im Klimakterium

Der Effekt von Wachstumshormon auf die menschlichen Alterungsprozesse. Teil 2

Neue Therapien (post-)menopausaler Symptome

Pubertas tarda bei hypogonadotropem Hypogonadismus